Screener
Acadia Pharmaceuticals ACAD Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Acadia Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's debt-to-equity?
- Acadia Pharmaceuticals (ACAD) reported debt-to-equity of 0.1× in Q2 2026.
- How has Acadia Pharmaceuticals's debt-to-equity changed year-over-year?
- Acadia Pharmaceuticals's debt-to-equity decreased by 17.5% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Acadia Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's debt-to-equity has grown at a -11.7% compound annual growth rate (CAGR), from 0.1× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Acadia Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude